CN1168472C - Chinese medicine prepn for treating lupus erythematosus - Google Patents
Chinese medicine prepn for treating lupus erythematosus Download PDFInfo
- Publication number
- CN1168472C CN1168472C CNB02109859XA CN02109859A CN1168472C CN 1168472 C CN1168472 C CN 1168472C CN B02109859X A CNB02109859X A CN B02109859XA CN 02109859 A CN02109859 A CN 02109859A CN 1168472 C CN1168472 C CN 1168472C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- lupus erythematosus
- preparation
- radix
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a traditional Chinese medicine preparation for treating lupus erythematosus. The purely natural Chinese herbal medicines of rhubarb, magnesium sulfate, scutellaria, chicken's gizzard-membrane, cortex moutan root-bark of tree peony, antelope horn, medicated leaven, largehead atractylodes rhizome and licorice are adopted and are rigidly screened and respectively processed according to a prescription of a traditional Chinese medicine theory, and a modern technique preparation method is combined, and the Chinese medicine preparation for treating the lupus erythematosus is made by combination. The preparation is made of the pure Chinese herbal medicines. The present invention has the advantages of little toxic side effect, resolution of current problems, elimination of root causes, conspicuous curative effect, rapid disappearance of clinical symptoms and no recurrence phenomenon after cure.
Description
Technical field:
The present invention relates to treat the medicine of lupus erythematosus, is to disclose a kind of Chinese medicine preparation for the treatment of the lupus erythematosus disease furtherly, belongs to the technical field of pharmaceuticals of Chinese traditional treatment lupus erythematosus.
Background technology:
At present, treatment lupus erythematosus disease is for doctor trained in Western medicine, just with hormone medicine as: " prednisone " kept, long-time use, the hormones untoward reaction appears in human body; Should disease use medicines such as " lupus pill ", " LIUWEI DIHUANG WAN " always for Chinese traditional treatment, though have certain therapeutic effect clinically, relatively severity, recurrence easily of bounce-back after the drug withdrawal.In a word, the tangible Drug therapy lupus erythematosus of inefficacy disease still at present.
Summary of the invention:
The present invention discloses a kind of Chinese medicine preparation for the treatment of lupus erythematosus, heat-clearing and toxic substances removing, and strengthening vital QI to eliminate pathogenic factors, the living marrow that nourishes blood is fundamentally treated the lupus erythematosus disease.
The present invention is according to pathogenesis and the Therapeutic Principle of motherland's traditional Chinese medical science traditional theory to the lupus erythematosus disease, in conjunction with the modern medicine achievement, selected pure Chinese herbal medicine with benefiting qi and nourishing blood, life essence-filling, marrow-benefitting, kidney and spleen invigorating function, make pharmaceutical preparation through science, be used to remove the pathogenesis of lupus erythematosus, make body no longer produce the situation of uric acid surplus.
Of the present invention is the Chinese medicine preparation of being made by ratio of weight and the number of copies by following medicine:
Radix Et Rhizoma Rhei 20~35, magnesium sulfate 50~80, Radix Scutellariae 57~70, Endothelium Corneum Gigeriae Galli 120~150,
Cortex Moutan 50~100, Cornu Saigae Tataricae 2~4, Massa Medicata Fermentata 100~120, the Rhizoma Atractylodis Macrocephalae 100~130,
Radix Glycyrrhizae 100~120.
Preferred prescription (by ratio of weight and the number of copies):
Radix Et Rhizoma Rhei 25, magnesium sulfate 65, Radix Scutellariae 57, Endothelium Corneum Gigeriae Galli 135, Cortex Moutan 85, Cornu Saigae Tataricae 4, Massa Medicata Fermentata 110, the Rhizoma Atractylodis Macrocephalae 110, Radix Glycyrrhizae 100.
Processing procedure: take by weighing said medicine in proportion, half fine powder that is ground into about 80 orders wherein is stand-by, four times of water gagings of another false add decoct twice, and each 2 hours, collecting decoction, filter, filtrate is concentrated into relative density 1.20~1.25 (80~85 ℃), and with above-mentioned fine powder mix homogeneously, xeraphium becomes fine powder, with 60% ethanol is that wetting agent is made granule, drying, granulate, sterilization packaging.
Above-mentioned medicament can be a said dosage form on any pharmaceutics.
China's theory of Chinese medical science is thought: the sea of gastric qi blood, and have only taste vigorous, QI and blood is just living to some extent, the vigorous ability of QI and blood " in healthy energy deposits, heresy can not in ".The used Chinese medicine of the present invention, major part have the effect of heat-clearing and toxic substances removing, cool liver function of gallbladder promoting.Consider that this disease mostly is taste two void, so in the side, added the medicine of relevant invigorating the spleen and benefiting QI.The combination principle of preparation of the present invention: with the Radix Et Rhizoma Rhei is monarch drug, and strength is swift and violent, cleanses gastrointestinal, weeds out the old and bring forth the new, and the poison of dispelling is evil and outer; Magnesium sulfate is ministerial drug, heat-clearing and toxic substances removing, cool liver function of gallbladder promoting, refreshment; Assistant is with Radix Scutellariae, Cortex Moutan, Cornu Saigae Tataricae, bowel relieving stomach, the cool liver of removing heat from blood, detoxifcation cephalocathartic; The compatibility Rhizoma Atractylodis Macrocephalae, Endothelium Corneum Gigeriae Galli, Massa Medicata Fermentata, Radix Glycyrrhizae are used for strengthening the spleen and nourishing the stomach, thick intestinal, beneficial vim and vigour, antiviral so that the poison of dispelling evil in outside.
Usage and consumption: oral.Formulation rate of the present invention can be according to variations such as route of administration, patient age, body weight, disease type and the orders of severity, and daily dose is 10~16 grams.Each 5~7g, takes with eliminating cold for resuscitation water or yellow wine and to take after mixing it with water at every day three times.
For showing the therapeutic effect of medicine of the present invention, selected 200 examples suffer from the patient of lupus erythematosus disease through hospital diagnosis, take medicine of the present invention and treat, and carry out statistical analysis through system's clinical observation and are summarized as follows:
One, curative effect determinate standard
Clinical cure: face red spot disappears, and health does not have uncomfortable reaction, does not see the recidivist more than 1 year.
Effectively: the face red spot speckle obviously diminishes, and color shoals.
Produce effects: face red spot speckle part diminishes,
Invalid: the face red spot no change.
Two, therapeutic outcome
200 routine lupus erythematosus disease patients, clinical cure 5 examples (2.5%); Produce effects 131 examples (65.6%); Invalid 7 examples of effective 57 examples (28.5%) (3.5%).Total effective rate is 96.5%.
Good effect of the present invention is: preparation is that pure Chinese herbal medicine is made, and toxic and side effects is little, and treating both the principal and secondary aspects of a disease is evident in efficacy, and clinical symptom disappearance is rapid, cures the no rebound phenomena in back.
The specific embodiment:
Embodiment 1
Take by weighing Radix Et Rhizoma Rhei 25g, magnesium sulfate 65g, Radix Scutellariae 57g, Endothelium Corneum Gigeriae Galli 135g, Cortex Moutan 85g, Cornu Saigae Tataricae 4g, Massa Medicata Fermentata 110g, Rhizoma Atractylodis Macrocephalae 110g, Radix Glycyrrhizae 100g.Half fine powder that is ground into about 80 orders wherein is stand-by, four times of water gagings of another false add decoct twice, each 2 hours, collecting decoction filters, and filtrate is concentrated into relative density 1.20~1.25 (80~85 ℃), with above-mentioned fine powder mix homogeneously, xeraphium becomes fine powder, is that wetting agent is made granule with 60% ethanol, drying, granulate, sterilization packaging.
Claims (2)
1, a kind of Chinese medicine preparation of lupus erythematosus is characterized in that being being made by the raw material of following weight portion:
Radix Et Rhizoma Rhei 20~35, magnesium sulfate 50~80, Radix Scutellariae 57~70, Endothelium Corneum Gigeriae Galli 120~150,
Cortex Moutan 50~100, Cornu Saigae Tataricae 2~4, Massa Medicata Fermentata 100~120, the Rhizoma Atractylodis Macrocephalae 100~130,
Radix Glycyrrhizae 100~120.
2, Chinese medicine preparation according to claim 1 is characterized in that being being made by the raw material of following weight portion:
Radix Et Rhizoma Rhei 25, magnesium sulfate 65, Radix Scutellariae 57, Endothelium Corneum Gigeriae Galli 135, Cortex Moutan 85, Cornu Saigae Tataricae 4, Massa Medicata Fermentata 110, the Rhizoma Atractylodis Macrocephalae 110, Radix Glycyrrhizae 100.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB02109859XA CN1168472C (en) | 2002-06-18 | 2002-06-18 | Chinese medicine prepn for treating lupus erythematosus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB02109859XA CN1168472C (en) | 2002-06-18 | 2002-06-18 | Chinese medicine prepn for treating lupus erythematosus |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1387886A CN1387886A (en) | 2003-01-01 |
CN1168472C true CN1168472C (en) | 2004-09-29 |
Family
ID=4740822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB02109859XA Expired - Fee Related CN1168472C (en) | 2002-06-18 | 2002-06-18 | Chinese medicine prepn for treating lupus erythematosus |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1168472C (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014153685A1 (en) * | 2013-03-29 | 2014-10-02 | Li Daihong | Chinese medicine capsule for treating lupus erythematosus |
-
2002
- 2002-06-18 CN CNB02109859XA patent/CN1168472C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1387886A (en) | 2003-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101461921B (en) | Medicinal composition for treating gynecopathy | |
CN101108226A (en) | Medicament treating rheumatism, rheumatoid, woman's wind, osteoproliferation and slipped disc illness | |
CN101919988B (en) | Medicine compound for curing rheumatism rheumatoid arthritis and preparation method thereof | |
CN101062372A (en) | Chinese herbal medicine preparation for dissolving hepatobiliary system calculi | |
CN101637589B (en) | Chinese medicinal composition for treating early stage bone injuries and soft tissue injuries and preparation method thereof | |
CN104758659A (en) | Traditional Chinese medicine paste for treating muscle and bone diseases | |
CN101658657B (en) | Drug for treating chronic cholecystitis | |
CN101912536B (en) | Medicinal composition for treating rheumatism and rheumatoid disease | |
CN1351872A (en) | Chinese herbal medicine for curing comedo and acne | |
CN1168472C (en) | Chinese medicine prepn for treating lupus erythematosus | |
CN102327395B (en) | Pharmaceutical composition for treating postpartum persistent lochia and preparation method thereof | |
CN100579544C (en) | Chinese medicament preparation for treating cholecystitis and gall-stone as well as preparation method thereof | |
CN1253196C (en) | Medicine for treating colitis | |
CN101983666A (en) | Traditional Chinese medicine composition for treating rheumatism and preparation method thereof | |
CN102018815A (en) | Chinese medicine preparation for treating tuberculosis of lumbar spine | |
CN102125612B (en) | Traditional Chinese medicine preparation for treating acute lumbar sprain | |
CN101590166A (en) | A kind of Chinese medicine composition that is used for the treatment of gout and preparation method thereof | |
CN1168473C (en) | Chinese medicine prepn for treating arterioscleriosis | |
CN102836346B (en) | Traditional Chinese medicine for treating lumbar disc herniation | |
CN1113667C (en) | Medicine for treating rheumatic and rheumatoid diseases | |
CN106581468A (en) | Preparation method of traditional Chinese medicine capable of treating gastric ulcer | |
CN105194526A (en) | Traditional Chinese medicine for treating hepatic calculi | |
CN1318402A (en) | Medicine for traumatic fracture pain | |
CN1232296C (en) | Chinese herbal medicine preparation for treating bone and muscle injuries | |
CN114209738A (en) | Traditional Chinese medicine composition and traditional Chinese medicine liquor for clearing heat, dispelling wind and dredging collaterals and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040929 |